ClinicalTrials.gg
CompletedNCT02121002Updated Jun 16, 2021Results posted

Study Comparing a Generic Diclofenac Sodium Topical Gel, 1% to Voltaren in the Treatment of Subjects With Osteoarthritis of the Knee

A Phase 3 interventional study of Diclofenac Sodium Topical Gel, 1% and Voltaren Topical Gel, 1% in Osteoarthritis, sponsored by Amneal Pharmaceuticals, LLC. Completed at 23 sites in India. Open to participants aged 35 Years and older. Per ClinicalTrials.gov, last updated 2021-06-16.

Sponsored by Amneal Pharmaceuticals, LLC · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,176
Allocation
Randomized
Ages
35 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 23 studies in Osteoarthritis with a site in India — none open to participants now, none under way, none of them phase 3. Osteoarthritis · India.

Enrollment
3rd of 21
1,176 · median 76
Started
2014
the only one that year
Phase 3
2 of 23
none open now
Registered
12th of 23
by date
Lead sponsor
1 of 23
Amneal Pharmaceuticals, LLC

Among the 23 studies in Osteoarthritis with a site in India, this one is the 3rd largest by enrollment of the 21 interventional ones that give a count, is the only one that started in 2014, is one of 2 in phase 3, and was the 12th registered.

Osteoarthritis

2,978 studies on the registry are indexed under Osteoarthritis; 438 are open to participants now.

Browse Osteoarthritis studies →

Open to participants now

None of the 23 studies in Osteoarthritis with a site in India is open now. The open studies under Osteoarthritis, anywhere →

Who these studies take

Of the 285 Osteoarthritis studies recruiting now, 158 (55%) set no upper age limit and 70 (25%) stop at 75 or younger; 22 take children under 18; 31 take healthy volunteers.

This study: 35 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 23 studies in Osteoarthritis with a site in India as a file.
02

Study summary

To establish the therapeutic equivalence and safety of a generic Diclofenac Sodium Topical Gel, 1% with Voltaren® Gel 1% in subjects with osteoarthritis of the knee.

03

Conditions studied

  • Osteoarthritis

Browse trials for

Keywords

  • Knee
04

Who can participate

Ages eligible
35 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy, ambulatory male or non-pregnant female subjects aged ≥ 35 years with a clinical diagnosis of OA of the knee.
  • Had an X-ray of the target knee, taken no more than 1 year before baseline, showing evidence of OA with Kellgren-Lawrence grade 1-3 disease.
  • After discontinuing all pain medications for at least 7 days, has at least moderate pain on movement for target knee
  • If female and of , agree to abstain from sexual intercourse or use a reliable method of during the study
  • Able to tolerate rescue medication with paracetamol/acetaminophen.

Exclusion criteria

Exclusion Criteria:

  • Pregnant or lactating or planning to become pregnant during the study period.
  • X-ray showing evidence of OA with Kellgren-Lawrence grade 4 disease.
  • History of OA pain in the contralateral knee requiring medication within 1 year prior to screening.
  • After discontinuing all pain medications for at least 7 days, has a baseline score of ≥20 mm on a 0-100 mm Visual Analog Scale (VAS) for the contralateral knee immediately prior to randomization.
  • History of secondary OA, rheumatoid arthritis, chronic inflammatory disease or fibromyalgia.
  • History of asthma, hypertension, myocardial infarction, thrombotic events, stroke, congestive heart failure, impaired renal function or liver disease.
  • History of gastrointestinal bleeding or peptic ulcer disease.
  • Use of warfarin or other anticoagulant therapy within 30 days of study randomization.
  • Elevated transaminases at screening.
  • Use of ACE inhibitors, cyclosporine, diuretics, lithium or methotrexate, within 30 days of study randomization.
  • Concomitant use of or use within 30 days of study randomization.
  • Concomitant acetylsalicylic acid therapy other than a stable low dose used for cardiac prophylaxis taken for at least 3 months prior to enrollment and maintained throughout the duration of the study.
  • Known allergy to aspirin or nonsteroidal anti-inflammatory drug
  • Any other acute or chronic illness that could compromise the integrity of study data or place the subject at risk by participating in the study.
  • Receipt of any drug as part of a research study within 30 days prior to screening.
  • Previous participation in this study.
  • Any use between screening and baseline of a treatment or medication that may potentially confound study assessment that may potentially confound study assessment (e.g. use of topical analgesics or anti-inflammatory drugs).
  • Recent history of major knee injury or surgery.
  • Known history of positive
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
1,176 participants (actual)

Study arms

  • Experimental
    Diclofenac Sodium Topical Gel, 1%

    Diclofenac Sodium Topical Gel, 1%. 4 gm, 4 times a day for 4 weeks

    Drug: Diclofenac Sodium Topical Gel, 1%

  • Active comparator
    Voltaren Topical Gel, 1%

    Voltaren Topical Gel, 1%. 4 gm, 4 times a day for 4 weeks

    Drug: Voltaren Topical Gel, 1%

  • Placebo comparator
    Vehicle Diclofenac Sodium Topical Gel

    Vehicle Diclofenac Sodium Topical Gel. 4 gm, 4 times a day for 4 weeks

    Drug: Vehicle Diclofenac Sodium Topical Gel

Interventions

  • DrugDiclofenac Sodium Topical Gel, 1%

    Opaque, white gel

  • DrugVoltaren Topical Gel, 1%

    Opaque, white gel

  • DrugVehicle Diclofenac Sodium Topical Gel

    Opaque, white gel

06

What researchers measure

Primary outcomes

  1. Change From Baseline to 4 Weeks in WOMAC Pain Score

    Mean change from baseline to week 4 in the Western Ontario McMaster Osteoarthritis (WOMAC) pain score: 5-point Likert scale: none=o, mild=1, moderate=2, severe=3, extreme=4

    Time frame: Baseline and Week 4

07

Results

Posted Jun 16, 2021

Participant flow

Participant flow — Overall Study
MilestoneDiclofenac Sodium Topical Gel, 1%Voltaren Topical Gel, 1%Vehicle Diclofenac Sodium Topical Gel
Started392393391
Completed385389381
Not completed7410
Withdrew: Physician decision200
Withdrew: Withdrawal by subject314
Withdrew: Protocol violation124
Withdrew: Concomitant therapy011
Withdrew: Others101

Outcome measures

PrimaryChange From Baseline to 4 Weeks in WOMAC Pain Score

Mean change from baseline to week 4 in the Western Ontario McMaster Osteoarthritis (WOMAC) pain score: 5-point Likert scale: none=o, mild=1, moderate=2, severe=3, extreme=4

Time frame:
Baseline and Week 4
Reported as:
Least squares mean · score on a scale
Change From Baseline to 4 Weeks in WOMAC Pain Score
score on a scaleDiclofenac Sodium Topical Gel, 1%Voltaren Topical Gel, 1%Vehicle Diclofenac Sodium Topical Gel
Change From Baseline to 4 Weeks in WOMAC Pain Score2.2332 ± 0.11602.0287 ± 0.1157-0.6387 ± 0.1172

Adverse events

Collected over The over all time frame for any the Adverse Events is maximum 9days starting from date of appearance to date of disappearance.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Diclofenac Sodium Topical Gel, 1%0/391 (0%)0/391 (0%)2/391 (0.5%)
Voltaren Topical Gel, 1%0/393 (0%)0/393 (0%)2/393 (0.5%)
Vehicle Diclofenac Sodium Topical Gel0/391 (0%)0/391 (0%)3/391 (0.8%)
Most frequent other events
Most frequent other events
EventDiclofenac Sodium Topical Gel, 1%Voltaren Topical Gel, 1%Vehicle Diclofenac Sodium Topical Gel
Gastrooesophageal reflux diseaseGastrointestinal disorders0/3910/3931/391
Oedema,General disorders1/3910/3930/391
Nasopharyngitis CoughInfections and infestations0/3910/3931/391
PyrexiaGeneral disorders0/3911/3931/391
Pruritus and Rash PruriticSkin and subcutaneous tissue disorders1/3910/3930/391
HeadacheNervous system disorders0/3911/3930/391

Baseline characteristics

Baseline participants in the Safety population.

Age, Customized
Age, Customized(Participants)Diclofenac Sodium Topical Gel, 1%Voltaren Topical Gel, 1%Vehicle Diclofenac Sodium Topical GelTotal
<= 18 years0000
between 18 and 65 years3573513541062
>=65year344237113
Sex: Female, Male
Sex: Female, Male(Participants)Diclofenac Sodium Topical Gel, 1%Voltaren Topical Gel, 1%Vehicle Diclofenac Sodium Topical GelTotal
Female255244254753
Male136149137422
08

Study locations

23 sites
  • Sunshine Hospitals
    Secunderabad, Andhra Pradesh 500003, India
  • King George Hospital
    Visakhapatnam, Andhra Pradesh 530002, India
  • King George Hospital
    Visakhapatnam, Andra Pradesh 530002, India
  • Rathi Orthopedic and Research Centre
    Ahmedabad, Gujarat 380 015, India
  • B. J. Medical College & Hospital
    Ahmedabad, Gujarat 380016, India
  • GMERS Medical College and Hospital
    Ahmedabad, Gujarat 380061, India
  • Shir Hatkesh Sarvajanik Tabibi Chikitsha Kendra
    Junagadh, Gujarat 362 001, India
  • Centre For Knee Surgery
    Vadodara, Gujarat 390007, India
  • Shree Giriraj Multispeciality Hospital
    Rajkot, Gujurat 360007, India
  • St Johns Medical College
    Bangalore, Karnataka 560034, India
  • K L E Societys Jawaharlal Nehry Medical College
    Belgaum, Karnataka 590010, India
  • Mysore Medical College
    Mysore, Karnataka 570001, India
  • Government Medical College, Calicut
    Calicut, Kerala 673008, India
  • Psm Dept Ltmmc & Ltmg Hospital
    Mumbai, Maharashtra 400022, India
  • Government Medical College
    Nagpur, Maharashtra 440009, India
  • Jasleen Hospital
    Nagpur, Maharashtra 440010, India
  • Lata Mangeshkar Hospital
    Nagpur, Maharashtra 440019, India
  • Bj Medical College
    Pune, Maharashtra 411001, India
  • Malpani Multispeciality Hospital
    Jaipur, Rajasthan 302023, India
  • Apollo Speciality Hospitals
    Madurai, Tamil Nadu 625020, India
  • M V Hospital and Research Centre
    Lucknow, Uttar Pradesh 226 003, India
  • King Georges Medical University
    Lucknow, Uttar Pradesh 226003, India
  • Goa Medical College
    Goa, 403716, India
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2014, a primary completion of Oct 2014 and a completion of Dec 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2021, 6 years 8 months after primary completion. A results delay was requested in Jun 2015.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 21, 2014
First posted
Apr 23, 2014
Start
Apr 2014
Primary completionActual
Oct 2014
CompletionActual
Dec 2014
Results delay requested
Jun 23, 2015
Results first posted
Jun 16, 2021
Last update
Jun 16, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 16, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02121002
Collaborators
Sristek Clinical Research Solutions Limited
Responsible party
Sponsor
First posted
Apr 23, 2014
Start date
Apr 2014
Primary completion
Oct 2014
Completion
Dec 2014
Results posted
Jun 16, 2021
Last update
Jun 16, 2021

Study contacts

Prayag Shah, MD
study director · Amneal Pharmaceuticals, LLC

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion